March Insider Buying GUTS 17,901 @ $1.28 31,000 @ $1.20 8,550 @ $1.17 16,129 @ $1.26 8,550 @ $ 1.17 Ok some of those lot amounts are a little wonky. And the CEO made a large sale the month before at $1.84////
SOMETHING UP WITH Poet Technologies call volume above normal and directionally bullish Jun 25, 2025 at 01:25 PM Bullish option flow detected in PoetTechnologies (POET) with 14,698 calls trading, 5x expected, and implied vol increasing over 16 points to 63.32%. Aug-25 4 calls and Jan-27 10 calls are the most active options, with total volume in those strikes near 3,700 contracts. The Put/Call Ratio is 0.03. Earnings are expected on August 14th.
LNW Light & Wonder, Inc.- TO BE honest I had no idea a court case was holding us back I should of been read up on that. Thankfully it looks like good news... Now the stk can move. $94.48 +8.66 (+10.09%)4:00 PM 06/25/25 NASDAQ | $USD | Post-Market: $94.70 +0.22 (+0.23%) 6:02 PM
Many people ask me how I got so good at TA. And I usually say TA is like good porn. You know it when you see it. Basically I can make any chart say what I want it to say if I am so inclined. The art is in being agnostic and realistic. Sometimes it pays to take a longer view. And one of the most powerful charts is Electronic Arts. What if I told you this is the ultimate channel stock and for FIVE YEARS has been going back and forth between $125-$150/ NOW-$157 Bit of a B/O A move now over $167 (2024 high) indicates much more upside. I'm looking for $220+
1/31 2025 Vol surge (55 mil traded) REBN skyrockets to $5.35 from $2.40. Then corrects to $3.72 <--- remember that then extends to $7.32. Then comes a painful swoon. 4/24 it hits $2.80 and then flat lines. This is a giant pennant or cone of shame. The most likely outcome here is a vertical spike up. But vol is puke. average vol get this 77K ZZZzzzzzzzzzzzzzz. This did 55 mil and 66 mil on it's break out. Strange. Forgotten and dangerous. Cold Brew Moment? RTD Cold Brew Program Nears Completion:Reborn Coffee’s Ready-to-Drink (RTD) Cold Brew line, developed in partnership with global beverage solutions provider Finlays, is entering the final stages of production. As part of this program, Reborn is finalizing a direct sourcing agreement with Gualanday, a high-elevation coffee farm in Colombia, to supply a full container of premium Colombian green coffee beans. These beans will be roasted and brewed exclusively for the RTD product, supporting a fully traceable, farm-to-RTD can supply chain. About Reborn Coffee Reborn Coffee, Inc. (NASDAQ: REBN) is a California-based specialty coffee retailer focused on delivering high-quality, handcrafted coffee experiences. With a growing global footprint and a dedication to innovation, Reborn is redefining the coffeehouse model through its premium products and technology-forward initiatives. Look for a 1mil+ vol day and pounce. SHENZHEN, China, March 04, 2025 (GLOBE NEWSWIRE) -- Reborn Coffee Inc. (Nasdaq: REBN), a leader in the specialty coffee market, has partnered with Eachome Shopping, a major retail platform under Shenzhen Media Group, to expand its retail footprint across China. Reborn Coffee and Eachome Shopping
ST T-$3.72<------- •USD Reborn Coffee, Inc.(REBN) 2.6400 -0.0600 (-2.22%) At close: 4:00:00 PM EDT 2.8062 +0.17 +(6.30%) After hours: 6:55:13 PM EDT
On June 10, Raymond James resumed coverage of Tectonic Therapeutic, Inc. (NASDAQ:TECX) with an Outperform rating and set a $76 price target.
Raymond James reasoned that for Tectonic Therapeutic, Inc. (NASDAQ:TECX), its lead asset, TX45, offers one of the most attractive risk-reward propositions in the biotech landscape, which is currently experiencing favorable skew and suppressed valuations. The ongoing Phase 2 by Tectonic Therapeutic, Inc. (NASDAQ:TECX) targets a high unmet need indication, favorably aligning with relaxin’s multi-modal mechanism of action, according to the firm. Tectonic Therapeutic, Inc. (NASDAQ:TECX) is a clinical-stage biotechnology company that discovers and develops therapeutic proteins and antibodies modulating the activity of G protein-coupled receptors (GPCR). The company develops a proprietary technology platform called GEODe to develop and discover GPCR-targeted biologic medicines. In March 2025, Tectonic Therapeutic had US$306m in cash, and was debt-free. Looking at the last year, the company burnt through US$63m. That means it had a cash runway of about 4.9 years as of March 2025.
Tectonic Therapeutic(TECX) The first ‘Perfect 10’ stock we’ll look at here is a biopharmaceutical research firm, Tectonic Therapeutic. Tectonic is working at both the preclinical and clinical stages, focusing its efforts on the development of G-Protein Coupled Receptors, or GPCRs, into a line of new drug candidates. GPCRs have an important role, as receptor molecules, as regulators in several human biological functions. They appear on cell surfaces and are actively involved in regulating such vital functions as blood pressure regulation, glucose metabolism, immune function, and neuronal signalling. Molecules with such varied actions in the human body are bursting with potential for medical research – and Tectonic is working to unlock that potential. The company has created a proprietary drug development platform, dubbed GEODe, which it uses in its discovery efforts for new biologic medicines to add to its research pipeline. Currently, Tectonic has several lines in the preclinical discovery stage, and one, TX45, in the human trial clinic. TX45 is under investigation as a potential treatment for high blood pressure in the circulatory system of the lungs, a dangerous condition known as pulmonary hypertension. The drug candidate is an ‘Fc-relaxin fusion protein,’ with potential to become the best in its class, and Tectonic is studying its efficacy in the treatment of Group 2 pulmonary hypertension. The drug’s action leverages vasodilatory and anti-fibrotic properties of relaxin. Tectonic has had some success with TX45 in the clinical studies. In September of last year, the company released favorable data from the Phase 1a study, and in January of this year it followed that data with another set of favorable interim results, on the Phase 1b stage of the study, in patients with Group 2 pulmonary hypertension in HFpEF. This coming May, the company will present additional Phase 1b data to the European Society of Cardiology (ESC) Heart Failure 2025 Congress. The drug is currently undergoing a Phase 2 clinical trial, with results expected next year. We should note that, despite these successes in the trial clinic, shares in TECX are down 56% so far this year. The stock’s decline began in January, after the pharma giant Eli Lilly terminated the clinical studies of its kidney disease drug candidate volenrelaxin. The termination was due to concerns that the drug was not proving efficacious; the negative impact on TECX shares came because volenrelaxin is in the same class of drugs, relaxin mimetics, as TX45. The failure of volenrelaxin has caused analysts and investors to worry about the efficacy of Tectonic’s lead candidate – worries that only a series of positive trial results will allay. Despite concerns surrounding the broader relaxin drug class, Mizuho analyst Uy Ear sees substantial promise in the company’s TX45 candidate and argues that the market is drastically undervaluing its potential.<------- “We like TECX as we believe: (1) The stock price reflects near zero value for TX45, which we believe has $3.3B unadjusted/$1.2B adjusted peak sales potential in CpCPH with HFpEF alone. There are also multiple scenarios for TX45 to treat the larger Group 2 PH, which would lead to significant upside; (2) While there are concerns about the ineffectiveness of the relaxin class, we see limited read-through from Lilly terminating volenrelaxin’s Phase 2 for futility, given the different conditions (heart failure vs TX45’s Group 2 PH) and continued validation of the MoA from AstraZeneca’s ongoing AZD3427 Phase 2 in Group 2 PH; (3) The consistency and clinically relevant magnitude of the improvements — left ventricular function and pulmonary hemodynamics — observed in the Phase 1b hemodynamic data will likely translate to clinical benefit in PH-HFpEF; and (4) Strong cash position (~$326M in 1Q25) with runway into 4Q28 and to complete the Phase 2 trial for TX45 and the Phase 1 and Phase 2 trials for TX2100, provide additional potential catalysts for the stock,” Ear opined. With that, Ear rates the shares as Outperform (i.e., Buy) and sets a $51 price target—implying the stock could soar by 152% over the next year. Overall, there are 5 recent analyst reviews of this stock, and they are all unanimously positive – giving TECX shares a Strong Buy consensus rating. The stock’s $20.23 trading price and $74.25 average target price together suggest a hefty 267% one-year upside potential.